SinuSys CEO Thomas Schreck and CMO Dr. Jerome Hester tell MassDevice.com how they hope to replace sinus surgery with a simple, in-office procedure and how a doctor and his patient formed a company together.
Tom Roberts, CEO of San Antonio, Texas-based startup Invictus Medical discusses the company's approach to preventing the cranial deformation plagiocephaly, also known as flattening of the skull, that affects up to 30% of newborns.
Cardiologist Dr. Darrel Francis finds himself attempting once again to drag the conversation back from the edge of hyperbole as the market reacts to the lackluster outcome of Medtronic's highly anticipated Symplicity HTN-3 trial of renal denervation in treatment of hypertension.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Market pressures weigh heavy on medtech in 2013, with M&A activity down 16% and FDA approvals down 44% year-over-year, but at least it wasn't the decade's worst period.
Last year was a tough one for the medical device industry, with acquisition activity down, M&A dollars cut in half and FDA approvals slashed, but at least it wasn't the worst year that medtech has faced in the last decade – 2009 still holds that title.
Biotherapeutics maker Vital Therapies raises $14 million in an equity financing round ahead of its revived initial public offering.
Bio-artificial liver maker Vital Therapies is prepared to take another run at its initial public offering, months after deciding to put off the IPO to await more favorable market conditions.
The California biotech company filed updated registration statements signaling its intent to launch the IPO, wiping clean the pricing set in November 2013. The new offering cap and per-share pricing have yet to be announced.
A federal appeals court applies the U.S. Supreme Court's decision in a lawsuit between Medtronic and Boston Scientific over pacemaker patents, remanding the case back to a lower court for an invalidity decision.